Clinical trials for Wolfram syndrome neurodegeneration: Novel design, endpoints, and analysis models
PLOS One · 2025
DOI: 10.1371/journal.pone.0321598 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Guoqiao Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Washington University in St Louis School of Medicine, St Louis, Missouri, United States of America. Hauptthemen laut MEDLINE: Wolfram Syndrome, Clinical Trials as Topic, Research Design. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, National Institutes of Health, Snow Foundation.
Abstract (Originalsprache)
Objective
Wolfram syndrome, an ultra-rare condition, currently lacks effective treatment options. The rarity of this disease presents significant challenges in conducting clinical trials, particularly in achieving sufficient statistical power (e.g., 80%). The objective of this study is to propose a novel clinical trial design based on real-world data to reduce the sample size required for conducting clinical trials for Wolfram syndrome.
Methods
We propose a novel clinical trial design with three key features aimed at reducing sample size and improve efficiency: (i) Pooling historical/external controls from a longitudinal observational study conducted by the Washington University Wolfram Research Clinic. (ii) Utilizing run-in data to estimate model parameters. (iii) Simultaneously tracking treatment effects in two endpoints using a multivariate proportional linear mixed effects model.
Results
Comprehensive simulations were conducted based on real-world data obtained through the Wolfram syndrome longitudinal observational study. Our simulations demonstrate that this proposed design can substantially reduce sample size requirements. Specifically, with a bivariate endpoint and the inclusion of run-in data, a sample size of approximately 30 per group can achieve over 80% power, assuming the placebo progression rate remains consistent during both the run-in and randomized periods. In cases where the placebo progression rate varies, the sample size increases to approximately 50 per group.
Conclusions
For rare diseases like Wolfram syndrome, leveraging existing resources such as historical/external controls and run-in data, along with evaluating comprehensive treatment effects using bivariate/multivariate endpoints, can significantly expedite the development of new drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurology, Washington University in St Louis School of Medicine, St Louis, Missouri, United States of America.
- Division of Biostatistics, Washington University in St Louis School of Medicine, St Louis, Missouri, United States of America.
- Department of Psychiatry, Washington University in St Louis School of Medicine, St Louis, Missouri, United States of America.
- Department of Radiology, Washington University in St Louis School of Medicine, St Louis, Missouri, United States of America.
ORCID-Profile: Guoqiao Wang, Zhaolong Adrian Li
Förderung
- NICHD NIH HHS
- National Institutes of Health
- Snow Foundation
- American Diabetes Association
Zitieren
APA
Wang, G., Li, Z. A., Chen, L., Lugar, H., & Hershey, T. (2025). Clinical trials for Wolfram syndrome neurodegeneration: Novel design, endpoints, and analysis models. PLOS One. https://doi.org/10.1371/journal.pone.0321598
Vancouver
Wang G, Li ZA, Chen L, Lugar H, Hershey T. Clinical trials for Wolfram syndrome neurodegeneration: Novel design, endpoints, and analysis models. PLOS One. 2025. doi:10.1371/journal.pone.0321598
BibTeX
@article{Wang2025,
author = {Wang, Guoqiao and Li, Zhaolong Adrian and Chen, Ling and Lugar, Heather and Hershey, Tamara},
title = {Clinical trials for Wolfram syndrome neurodegeneration: Novel design, endpoints, and analysis models},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0321598}
}
EUVIMED